The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
 
Rachel J. Cook
Consulting or Advisory Role - Syros Pharmaceuticals
Travel, Accommodations, Expenses - Syros Pharmaceuticals
 
Eytan Stein
Consulting or Advisory Role - Agios; Celgene; Pfizer
Research Funding - Agios; Celgene; GlaxoSmithKline; Seagen; Syros Pharmaceuticals
 
David P. Steensma
Stock and Other Ownership Interests - ARIAD
Consulting or Advisory Role - Akebia Therapeutics; Amgen; Celgene; H3 Biomedicine; Janssen Oncology; Novartis; Pfizer; Takeda
 
Mikkael A. Sekeres
Consulting or Advisory Role - Celgene; Millennium
 
Dale L. Bixby
No Relationships to Disclose
 
David Rizzieri
Consulting or Advisory Role - Abbvie; Novartis; Pfizer; Spectrum Pharmaceuticals; Teva
Speakers' Bureau - Celgene; Gilead Sciences; Incyte; Millennium (I); Seagen
 
Joseph G. Jurcic
Consulting or Advisory Role - Alexion Pharmaceuticals; Amgen; Bayer; Novartis; Seagen; Sunesis Pharmaceuticals
Research Funding - Actinium Pharmaceuticals (Inst); Astellas Pharma (Inst); Celgene (Inst); Daiichi Sankyo (Inst); FORMA Therapeutics (Inst); Kura Oncology (Inst); Seagen (Inst); Syros Pharmaceuticals (Inst)
 
Carlos Enrique Vigil
No Relationships to Disclose
 
Robert Redner
Stock and Other Ownership Interests - Biogen; GlaxoSmithKline; Johnson & Johnson; Medtronic; Merck
Research Funding - Bristol-Myers Squibb (Inst)
 
Gail J. Roboz
Consulting or Advisory Role - Agios; Amgen; Amphivena; Astex Pharmaceuticals; AstraZeneca; Boehringer Ingelheim; Celator; Celgene; Cellectis; CTI; Genoptix; GlaxoSmithKline; Janssen; Juno Therapeutics; MedImmune; MEI Pharma; Novartis; Onconova Therapeutics; Pfizer; Roche; Shire; Sunesis Pharmaceuticals
Research Funding - Abbvie (Inst); Agios (Inst); Astex Pharmaceuticals (Inst); Celgene (Inst); Cellectis (Inst); CTI (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); MEI Pharma (Inst); Moffitt (Inst); Novartis (Inst); Onconova Therapeutics (Inst); Pfizer (Inst); Sunesis Pharmaceuticals (Inst); Tensha Therapeutics (Inst)
Travel, Accommodations, Expenses - Amphivena; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Celator; Incyte; Janssen; Juno Therapeutics; MEI Pharma; Roche; Shire
 
Michael R. Savona
Stock and Other Ownership Interests - Karyopharm Therapeutics
Consulting or Advisory Role - Amgen; ARIAD; Celgene; CTI; Gilead Sciences; Karyopharm Therapeutics
Research Funding - Astex Pharmaceuticals (Inst); Sunesis Pharmaceuticals (Inst); TG Therapeutics (Inst)
 
Michael R. McKeown
Employment - Syros Pharmaceuticals
Stock and Other Ownership Interests - Syros Pharmaceuticals
 
Kristin Stephens
Employment - Syros Pharmaceuticals
Stock and Other Ownership Interests - Syros Pharmaceuticals
 
David A. Roth
Employment - Syros Pharmaceuticals
Stock and Other Ownership Interests - Syros Pharmaceuticals
 
Jorge E. Cortes
Consulting or Advisory Role - Amphivena Therapeutics; ARIAD; BiolineRx; Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Research Funding - Ambit BioSciences (Inst); ARIAD (Inst); Arog (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Immunogen (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst); Teva (Inst)